Adherence to Anticoagulant Therapy in Pediatric Patients Hospitalized With Pulmonary Embolism or Deep Vein Thrombosis

2015 ◽  
Vol 22 (3) ◽  
pp. 260-264 ◽  
Author(s):  
Rakesh R. Singh ◽  
Komal R. Gupte-Singh ◽  
James P. Wilson ◽  
Brady S. Moffett
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
Anticoagulant Therapy ◽  
Pediatric Patients ◽  
Vein Thrombosis ◽  
Deep Vein

PULMONARY EMBOLISM AFTER SURGICAL RESECTION OF A MENINGIOMA

Vestnik ◽  
2021 ◽  
pp. 118-121
Author(s):  
Е.К. Дюсембеков ◽  
Е.Б. Алгазиев ◽  
А.К. Жанисбаев ◽  
С.М. Анартаев ◽  
И.А. Канлов ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
Surgical Resection ◽  
Anticoagulant Therapy ◽  
Clinical Case ◽  
Massive Pulmonary Embolism ◽  
Multidisciplinary Teams ◽  
Vein Thrombosis ◽  
Surgical Methods ◽  
Deep Vein

В статье представлен клинический случай успешного лечения острой массивной тромбоэмболии лёгочной артерии у пациента после удаления менингиомы. Известно, что частота тромбозов глубоких вен нижних конечностей (ТГВ) в нейрохирургической практике достаточно высока, и может достигать 25-34%. ТГВ является основной причиной более грозной тромбоэмболии легочной артерии (ТЭЛА), частота которой составляет от 1,5% до 3%. На сегодняшний день медицина располагает несколькими эффективными инструментами лечения пациентов с ТЭЛА: от антикоагулянтной терапии до хирургических методов реперфузии. Благодаря слаженной работе в современных многопрофильных клиниках интервенционных кардиохирургов, реаниматологов и нейрохирургов, обеспечивающих своевременную и высокоспециализированную помощь, становится возможным спасение жизней пациентов даже с такой тяжелой и жизнеугрожающей патологией как острая массивная тромбоэмболия легочных артерий. The article presents a clinical case of successful treatment of acute massive pulmonary embolism in a patient after resection of a meningioma. The incidence of Deep vein thrombosis (DVT) in neurosurgical practice is astonishingly high as it might reach 25-34% in some reports, and represents the first cause for pulmonary embolism (PE), which incidence is thought to be between 1,5% and 3%. Nowadays there are several options for treating patients with pulmonary embolism: from anticoagulant therapy to surgical methods of reperfusion. Effective multidisciplinary teams and coordinated team in our clinics can save the lives of people with pulmonary embolism.

The Risk and Efficacy of Anticoagulant Therapy in the Treatment of Thromboembolic Complications in Patients with Primary Malignant Brain Tumors

Neurosurgery ◽  
1990 ◽  
Vol 27 (1) ◽  
pp. 74-77 ◽  
Author(s):  
Eric Altschuler ◽  
Hans Moosa ◽  
Robert G. Selker ◽  
Frank T. Vertosick
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
Anticoagulant Therapy ◽  
Warfarin Therapy ◽  
Oral Anticoagulant Therapy ◽  
Effective Means ◽  
Thromboembolic Complications ◽  
Intratumoral Hemorrhage ◽  
Vein Thrombosis ◽  
Deep Vein

Abstract Twenty-three patients with malignant glial neoplasms were treated with anticoagulant therapy for thromboembolic complications. Fifteen patients had deep vein thrombosis alone, and 8 patients had both deep vein thrombosis and pulmonary embolism. Serum prothrombin times were maintained at 1.25 times control for an average of 5.8 months per patient, for a total patient exposure to warfarin therapy of 132 patient-months (11 patient-years). Only 1 patient suffered a recurrent pulmonary embolism, and this occurred during an episode of gastrointestinal bleeding, when anticoagulant therapy had to be discontinued prematurely. All patients were followed with serial computed tomographic or magnetic resonance imaging scans, and no patient showed radiographic evidence of intratumoral hemorrhage either during or after warfarin therapy. One patient, who died from a large recurrent glioblastoma, was found at autopsy to have scattered foci of intratumoral hemorrhage. This series, together with a review of the available literature, suggests that oral anticoagulant therapy is both a safe and effective means of treating thromboembolic complications in patients with residual malignant glial tumors.

Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism

Blood ◽  
2014 ◽  
Vol 123 (12) ◽  
pp. 1794-1801 ◽  
Author(s):  
Clive Kearon ◽  
Elie A. Akl
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
High Risk ◽  
Anticoagulant Therapy ◽  
Low Risk ◽  
Risk Of Recurrence ◽  
Vein Thrombosis ◽  
Risk Of Bleeding ◽  
Deep Vein

Abstract It takes about 3 months to complete “active treatment” of venous thromboembolism (VTE), with further treatment serving to prevent new episodes of thrombosis (“pure secondary prevention”). Consequently, VTE should generally be treated for either 3 months or indefinitely (exceptions will be described in the text). The decision to stop anticoagulants at 3 months or to treat indefinitely is dominated by the long-term risk of recurrence, and secondarily influenced by the risk of bleeding and by patient preference. VTE provoked by a reversible risk factor, or a first unprovoked isolated distal (calf) deep vein thrombosis (DVT), has a low risk of recurrence and is usually treated for 3 months. VTE associated with active cancer, or a second unprovoked VTE, has a high risk of recurrence and is usually treated indefinitely. The decision to stop anticoagulants at 3 months or to treat indefinitely is more finely balanced after a first unprovoked proximal DVT or pulmonary embolism (PE). Indefinite anticoagulation is often chosen if there is a low risk of bleeding, whereas anticoagulation is usually stopped at 3 months if there is a high risk of bleeding. The decision to continue anticoagulation indefinitely after a first unprovoked proximal DVT or PE is strengthened if the patient is male, the index event was PE rather than DVT, and/or d-dimer testing is positive 1 month after stopping anticoagulant therapy.

scholarly journals When Can a Pulmonary Embolism and Deep Vein Thrombosis Patient Fly Safely Again on Airplane? A Case Report

2021 ◽  
Vol 7 (2) ◽  
Author(s):  
Lin S L ◽  
◽  
Lin W C ◽  
Hsu N W ◽  
◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
Case Report ◽  
Anticoagulant Therapy ◽  
Long Distance ◽  
Vein Thrombosis ◽  
Deep Vein ◽  
Current Guidelines ◽  
Acute Pe

There was no recommendation in the current guidelines for how long after the pulmonary embolism (PE) attack the patient can fly again safely on an airplane. A 45 years old female was admitted to our hospital because of deep vein thrombosis and acute PE. Due to persistent leg swelling and afraid of recurrent PE for long distance flights, this patient received four weeks anticoagulant therapy before flying. Eventually, she flew back safely. This report describes our preliminary experience for managing this patient with deep vein thrombosis and PE.

scholarly journals Daily Hospitalization Costs in Patients with Deep Vein Thrombosis or Pulmonary Embolism Treated with Anticoagulant Therapy

2015 ◽  
Vol 135 (2) ◽  
pp. 303-310 ◽  
Author(s):  
Joseph F. Dasta ◽  
Dominic Pilon ◽  
Samir H. Mody ◽  
Jessica Lopatto ◽  
François Laliberté ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
Anticoagulant Therapy ◽  
Vein Thrombosis ◽  
Hospitalization Costs ◽  
Deep Vein ◽  
Daily Hospitalization

Controlled Trial of the Sequential Use of Streptokinase and Ancrod in the Treatment of Deep Vein Thrombosis of Lower Limb

1977 ◽  
Vol 37 (02) ◽  
pp. 222-232 ◽  
Author(s):  
D. A Tibbutt ◽  
C. N Chesterman ◽  
E. W Williams ◽  
T Faulkner ◽  
A. A Sharp
Keyword(s):  
Deep Vein Thrombosis ◽  
Clinical Improvement ◽  
Anticoagulant Therapy ◽  
Lower Limb ◽  
Oral Anticoagulant ◽  
Controlled Trial ◽  
Oral Anticoagulant Therapy ◽  
Control Group ◽  
Vein Thrombosis ◽  
Deep Vein

SummaryTreatment with streptokinase (‘Kabikinase’) was given to 26 patients with venographically confirmed deep vein thrombosis extending into the popliteal vein or above. Treatment was continued for 4 days and the patients were allocated randomly to oral anticoagulant therapy or a course of treatment with ancrod (‘Arvin’) for 6 days followed by oral anticoagulant therapy. The degree of thrombolysis as judged by further venographic examination at 10 days was not significantly different between the 2 groups. The majority of patients showed clinical improvement but there was no appreciable difference between the groups at 3 and 6 months. Haemorrhagic complications were a more serious problem during the period of treatment with ancrod than during the equivalent period in the control group.

Sign in / Sign up

Export Citation Format

Share Document